Oculis Holding AG was incorporated under the laws of Switzerland on December 11, 2017. The Company is a clinical-stage biopharmaceutical company headquartered in Switzerland with extensive expertise in therapies for the treatment of eye diseases and is involved in the development of innovative drug candidates with the potential to address many eye diseases. Their focus is on advancing therapeutic candidates to treat major ophthalmic diseases that lead to vision loss, blindness or reduced quality of life. Their clinical portfolio currently includes three therapeutic drug candidates: OCS-01, OCS-02 and OCS-05. 

OCS

OCS Profile